AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-219648768/orphan-drug-designation-29.html" title="Facts and information about Orphan drug designation (29 Jan 2010): EU/3/09/712 (Recombinant kallikrein inhibitor, Voisin Consulting).">Orphan drug designation (29 Jan 2010): EU/3/09/712 (Recombinant kallikrein inhibitor, Voisin Consulting).</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
Orphan drug designation (29 Jan 2010): EU/3/09/712 (Recombinant kallikrein inhibitor, Voisin Consulting).
On 2 Feb 2010, the European Commission (EC) announced decision number C(2010)712 of 29 Jan 2010, the approval of EU orphan drug designation EU/3/09/712. The active ingredient is recombinant kallikrein inhibitor …
Related articles from newspapers, magazines, journals, and more
-
- Public summary of opinion on orphan designation: Recombinant kallikrein...
-
News wire article from: Chemical Business Newsbase
February 25, 2010
700+ words
-
- Committee for Orphan Medicinal Products Nov 2009 plenary meeting monthly...
-
News wire article from: Chemical Business Newsbase
November 11, 2009
700+ words
